COMPANY PROFILE

Delve Bio

Explore full profile

Providing Molecular Insights for the Precision Care of the Sickest Patients

Boston, United StatesFounded 2022Biotech & Life Sciences

Valuation $100–250M Last recorded · 2023

Headcount <100 Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

About Delve Bio

Delve.bio is a stealth biotech company focused on revolutionizing precision medicine through cutting-edge genomic technology. The company aims to provide molecular insights that significantly enhance the care of critically ill patients. Delve.bio operates in the precision medicine market, targeting healthcare providers and research institutions that require advanced genomic data to improve patient outcomes. The business model is likely centered around offering genomic analysis services and proprietary technology solutions to these clients, generating revenue through service fees and possibly licensing agreements. The company is well-funded and backed by experienced operators and investors in the biotech industry, ensuring robust financial and operational support. The co-founders bring a wealth of experience from various sectors, including research, clinical practice, and entrepreneurship, which positions the company strongly in its mission to transform patient care.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2022
Headquarters: Boston, United States
Employees: 43
Open positions: None listed
Dealroom signal: 84.2/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Precision Medicine, Spinout, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES AOther financing	Jun 2023	$35M	$140M	GV · Perceptive Advisors · Section 32	↗
SERIES AOther financing	Jan 2023	$36M	$143M	GV · Xontogeny	—

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Delve Bio website traffic

Latest recorded traffic for Delve Bio is 4.4K monthly website visits, down 12% over the last three months. Delve Bio's team grew 0% over the past year.

Latest monthly visits4.4K 3-month web change-12% 1-year team growth0%

Monthly website visitsApr 2023–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
TBTome BiosciencesTome Biosciences is the programmable gene insertion company	Watertown, United States	Operational	137	$309M	$512M
ATAtG TherapeuticsAt AtG, we develop novel classes of medicines and biomarkers to prevent cancer therapeutic resistance	L'Hospitalet de Llobregat, Spain	Operational
XIXilisDeveloping next generation technologies for precision medicine and drug discovery	Durham, United States	Operational
NTNucleome TherapeuticsDecoding the dark matter of the human genome to discover first-in-class precision medicine	Oxford, United Kingdom	Operational
PRPredxBioTissue-Based Decision Intelligence for Oncology	Bellevue, United States	Operational
FBFreeOx BiotechAdvancing Stroke Care through Innovation and Precision Medicine	Barcelona, Spain	Operational
OBOrionis BiosciencesPioneering technological innovation in genome-scale drug discovery and tunable molecular design of novel therapeutic drug modalities	Waltham, United States	Operational
VAVarinosOffering advanced clinical tests in reproductive medicine and obstetrics/gynecology	Tokyo, Japan	Operational